Vaxart wins $453M in BARDA funding for oral Covid-19 vaccine

Katherine Lewin

News Reporter

The Biomedical Advanced Research and Development Authority (BARDA) has granted up to $453 million to Vaxart to revive its work on an oral Covid-19 vaccine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vaxart wins $453M in BARDA funding for oral Covid-19 vaccine

Katherine Lewin

News Reporter

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Vaxart wins $453M in BAR­DA fund­ing for oral Covid-19 vac­cine

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Vaxart wins $453M in BARDA funding for oral Covid-19 vaccine

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life